Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts

Key Points

• Analysts: 21 firms cover Revolution Medicines with a consensus Buy rating (1 sell, 15 buy, 5 strong buy) and an average 12‑month target price of $78.94.
• Recent results: the company reported Q4 EPS of -$1.86, missing estimates by $0.30, and sell‑side analysts project -3.49 EPS for the current fiscal year; the stock carries a negative P/E, a market cap of $18.33B and a 52‑week range of $29.17–$124.49.
• Ownership activity: insiders have sold about 149,592 shares (~$15.0M) in the last 90 days (insider ownership 8.20%), while institutional investors own 94.34% of the stock with large new stakes from General Atlantic, Norges Bank, UBS and others.

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) have been given a consensus rating of "Buy" by the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, fifteen have given a buy recommendation and five have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $78.9412.

A number of analysts recently commented on the stock. Truist Financial upgraded shares of Revolution Medicines to a "strong-buy" rating in a report on Wednesday. UBS Group started coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a "buy" rating for the company. Evercore raised Revolution Medicines to a "strong-buy" rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Finally, Wedbush reissued an "outperform" rating on shares of Revolution Medicines in a research note on Friday, January 9th.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $92.51 on Friday. The business's 50-day moving average price is $100.37 and its 200 day moving average price is $78.70. The firm has a market cap of $18.33 billion, a P/E ratio of -15.65 and a beta of 0.99. Revolution Medicines has a 52-week low of $29.17 and a 52-week high of $124.49. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the business earned ($1.12) EPS. As a group, sell-side analysts predict that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Xiaolin Wang sold 2,010 shares of the company's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares of the company's stock, valued at $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Stephen Michael Kelsey sold 4,302 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the transaction, the insider owned 295,398 shares of the company's stock, valued at $29,386,193.04. This trade represents a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 149,592 shares of company stock valued at $15,010,732 over the last 90 days. 8.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently made changes to their positions in the company. General Atlantic L.P. purchased a new stake in shares of Revolution Medicines in the 3rd quarter valued at approximately $115,556,000. Norges Bank purchased a new position in Revolution Medicines during the 4th quarter worth approximately $195,568,000. Avoro Capital Advisors LLC purchased a new position in Revolution Medicines during the 4th quarter worth approximately $172,840,000. UBS Group AG raised its stake in Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company's stock valued at $245,954,000 after purchasing an additional 1,998,972 shares during the period. Finally, Polar Capital Holdings Plc lifted its holdings in shares of Revolution Medicines by 321.2% in the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company's stock valued at $160,398,000 after purchasing an additional 1,535,686 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.